| Title |
Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma
|
|---|---|
| Published in |
PharmacoEconomics, December 2018
|
| DOI | 10.1007/s40273-018-0740-4 |
| Pubmed ID | |
| Authors |
Frederick W. Thielen, Nasuh C. Büyükkaramikli, Rob Riemsma, Debra Fayter, Nigel Armstrong, Ching-Yun Wei, Vanesa Huertas Carrera, Kate Misso, Gill Worthy, Jos Kleijnen, Isaac Corro Ramos |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 47 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 5 | 11% |
| Student > Ph. D. Student | 5 | 11% |
| Student > Bachelor | 4 | 9% |
| Researcher | 4 | 9% |
| Other | 3 | 6% |
| Other | 7 | 15% |
| Unknown | 19 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 19% |
| Nursing and Health Professions | 4 | 9% |
| Economics, Econometrics and Finance | 3 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
| Unspecified | 2 | 4% |
| Other | 6 | 13% |
| Unknown | 20 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 December 2018.
All research outputs
#15,505,248
of 24,570,543 outputs
Outputs from PharmacoEconomics
#1,552
of 1,960 outputs
Outputs of similar age
#246,392
of 445,961 outputs
Outputs of similar age from PharmacoEconomics
#15
of 28 outputs
Altmetric has tracked 24,570,543 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,960 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 445,961 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.